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SocietyEtiology and features of osteoarthritis (OA)
OA is the most common form of arthritis1. Although the pre-
cise etiology of the disease in most cases is unknown, it is
generally accepted that OA is a multifactorial disorder
involving both genetic and environmental components2.
Genetic factors are either mutations or variations in genes
that result in defects or variability in cartilage matrix proper-
ties and chondrocyte metabolism. In the case of matrix
defects caused by mutations in matrix genes, age-
dependent cartilage degeneration may occur as a result of
even normal mechanical stresses on a joint. In the case of
inherited sequence variations in genes, some variations
may confer increased risk for OA3. Environmental factors in-
clude obesity, over-loading on joints, repetitive injury involv-
ing ligaments and menisci, loss of muscle strength and joint
malalignment. These conditions can result in abnormal me-
chanical stresses on the joint, leading to cartilage degener-
ation. Since OA can occur as a result of one or
a combination of these factors, investigating the detailed
pathogenic mechanisms in all these conditions remains
a formidable challenge. However, regardless of the nature
of the factor(s) that initiates the disease, the pathological
progression of OA follows a typical pattern4. The earliest
indication of pathological change is chondrocyte clustering
as a result of increased cell proliferation and a general up-
regulation of synthetic activity. Increased expression of
cartilage-degrading proteinases and matrix proteins sug-
gests an attempt at repair. Gradual loss of proteoglycans
appears in the surface region of articular cartilage and this
is followed by type II collagen degradation. Cracks develop
along the articular surface, producing the histological image
termed ﬁbrillation. At later stages of the disease, ﬁbrocarti-
lage forms, probably as a consequence of unsuccessful
attempts by chondrocytes to ﬁll in the cracks. Finally, osteo-
phytes, bony structures at the periphery of the joint surface,
form.
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Received 24 April 2007; revision accepted 24 April 2007.1The similarities in the pathologic progression of the dis-
ease, even when the initiating events are different, indicate
that there may be a common molecular sequence of events
underlying OA progression. Thus, studies of pathogenetic
changes, even in cases of more rare forms of OA, are likely
to provide signiﬁcant information about diseasemechanisms
and therapeutic targets for treating evenmore common forms
of the disease. During the past few years, mutations in genes
encoding type II, IX and XI collagens have been demon-
strated to be associated with an age-dependent articular
cartilage degenerative process that has all the histological
hallmarks of OA5e15. These genetic forms of OA in humans
clearly represent rare genetic subsets of the disease, but
studies of these genetic forms are likely to provide insights
into the pathogenesis of more common forms as well.
OA associated with mutations in types
IX and XI collagens in humans: multiple
epiphyseal dysplasia (MED) and
Stickler syndrome
MED,aheterogeneous groupof hereditary chondrodyspla-
sias characterized by early onset OA andmild short stature in
humans, is causedbymutations in type IXcollagen (COL9A1,
COL9A2, and COL9A3), cartilage oligomeric matrix protein
(COMP), or matrilin 316,17. Stickler syndrome18 is a relatively
mild form of osteochondrodysplasia caused by mutations in
the genes encoding type XI collagen chains (COL11A1 and
COL11A2) or type II collagen (COL2A1). Type II, IXandXI col-
lagens formcartilage collagen ﬁbrils19,20 that offer high tensile
strength and promote the retention of the highly hydrated pro-
teoglycans inarticular cartilage.Adefect in thestructural com-
ponents in thematrix, suchasmutations in type IX (MED)orXI
collagen (Stickler syndrome), results in disorganization of the
collagen network andmakes the articular cartilage less resis-
tant to the normal mechanical loading of the joint surface. Of
clinical interest is that OA in MED patients appears mostly in
knee joints, with the hip joint often spared from the degenera-
tiveprocess. In contrast, patientswithStickler syndromehave
OA in hips as well as in knees. Why knee joints are primarily
‘‘targeted’’ in MED patients is unknown. One plausible expla-
nation is that the shape of a joint, particularly a knee joint, is
a critical element in the maintenance of normal joint function.101
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patients with type IX collagen mutations, will unevenly allo-
cate the mechanical stresses on the joint. Therefore, OA in
knee joints of MED patients with type IX collagen mutations
may be the result of a combined effect of altered joint geome-
try and a defective matrix.
Mouse models for genetic forms of human
OA, type IX collagen-deﬁcient (Col9a1L/L)
and type XI collagen-deﬁcient (cho/D) mice
Pathological changes in human OA are complex and oc-
cur over a relatively long period of time in affected individ-
uals. Hence, an appropriate mouse OA model must show
a pathological alteration in joints similar to what is seen in
humans with the changes developing over time. Both
Col9a1/ and cho/þ mice possess these features of
human OA. Col9a1/ mice were generated by gene-
targeting21. The deletion of Col9a1 leads to the absence of
type IX collagen22. Col9a1/ mice develop normally with
the exception of a ﬂattening of knee joint surfaces and an in-
creased distance between the knee joint condyles. The
chondrodysplasia in the cho mouse strain is an autosomal-
recessive disorder23. We previously found that the defect
in homozygous cho/cho mice, which die at birth, is due to
a single nucleotide deletion in Col11a1 leading to a frame-
shift and premature termination of translation of the a1 chain
of type XI collagen and that the level of mRNA encoded by
the mutant Col11a1 is dramatically reduced24. Heterozy-
gous cho/þ mice develop normally without obvious skeletal
abnormalities at birth. Histological studies show that
Col9a1/ and cho/þ mice develop OA-like changes in
knee and temporomandibular (TM) joints starting at the
age of 3 months and a severe OA-like pathology over
9e12 months (normal life span of about 30 months on aver-
age)25,26. The OA-like phenotype in Col9a1/ mice is
a good model for the cartilage degenerative condition seen
in MED patients with type IX collagen mutations; the cho/þ
mice serve as a model for the degenerative cartilage condi-
tion seen in Stickler syndrome caused by type XI collagen
mutations. Importantly, we found that the expression of ma-
trix metalloproteinase 13 (Mmp-13) is increased in the artic-
ular cartilage of knee and TM joints in both Col9a1/ and
cho/þ mice at the age of 6 months. The level of Mmp-
derived type II collagen fragments (CII-f) is also increased
in both mutants, indicating that Mmp activity is elevated
as well. Interestingly, we have found that the expression of
discoidin domain receptor 2 (DDR2), a cell surface type II
collagen receptor, is also increased in mutant mice at
a time when the expression of Mmp-13 is upregulated.
MMP-13 in OA
A study by Verzijl et al.27 indicates that the half-life of car-
tilage collagen is 117 years. This suggests that chondro-
cytes may have a limited ability to produce type II
collagen in mature articular cartilage once the collagen is
degraded. Thus, type II collagen breakdown in articular
cartilage may be a ‘‘rate-determining’’ step in OA progres-
sion. Identiﬁcation of a drug that can prevent type II colla-
gen degradation may be able to prolong the progression
of OA and delay the need for joint replacement. Recent
studies suggest that MMP-13 (collagenase-3) is particularly
important in OA progression because of its ability to cleave
triple-helical type II collagen more efﬁciently than MMP-1(collagenase-1)28. MMP-13 cleaves the chains of type II col-
lagen at a Gly906eLeu907 site to generate two fragments
corresponding to 3/4 and 1/4 of the intact molecule. In addi-
tion, the enzyme can further cleave at a secondary site,
Gly909eGln910, within the smaller (1/4) fragment. MMP-13
is expressed at a very low level in normal articular cartilage,
but the expression of the enzyme is increased in human OA
articular cartilage29e32. This is consistent with the observa-
tion that constitutive expression of MMP-13 gene in mouse
cartilage results in OA-like changes in knee joints33. Tran-
scriptional analysis of the MMP-13 gene shows that the
human MMP-13 promoter contains a TATA box and binding
sites for transcription factors such as AP-1 (e.g., c-Fos/
c-Jun), PEA-3 and Runx2. Mutations in these binding sites
can partially or completely abolish the activity of the human
MMP-13 promoter34e38. Several signaling pathways in-
volved in the transcriptional regulation of MMP-13 expres-
sion in response to the stimulation by IL-1b and
ﬁbronectin fragments (FN-f) have been characterized in
chondrocytes39e44. IL-1b binding to its receptor results in
signaling through the JNK and p38 kinase cascades, but
not ERK1/2, and can also activate the NF-kB pathway.
The integrin a5b1 is a receptor for FN-f. After binding to
FN-f, the receptor is activated and interacts with proline-
rich tyrosine kinase-2 (PYK2) and the focal adhesion kinase
(FAK) to form a signaling complex. This complex can acti-
vate ERK, JNK and p38. Activation of the p38 pathway
increases the transcription of Runx2, whereas activation
of ERK results in the phosphorylation of Runx2 protein in
the cytoplasm and subsequent translocation to the nucleus.
Although the signaling pathways activated by the integrins
and cytokine receptors on chondrocytes play a signiﬁcant
role in the transcriptional regulation of MMP-13 expression
in chondrocytes, a certain degree of matrix damage would
be required to generate the FN-f, which induce the resident
chondrocytes to synthesize and release MMP-13 through
the integrin-mediated pathways.
One important question is whether any mechanism exists
at an early stage of OA to stimulate chondrocytes to synthe-
size and release MMP-13 prior to signiﬁcant degradation of
the cartilage. The results of our studies and those of others
suggest that DDR2 may provide such a mechanism on
chondrocytes (Fig. 1).
Fig. 1. Diagram showing a proposed timeline for the progression of
OA. At an early stage, activation of the collagen receptor DDR2
leads to upregulated expression of MMP-13. This results in gener-
ation of fragments of type II collagen and ﬁbronectin in the territorial
matrix. These fragments, as well as cytokines such as IL-1, further
stimulate signaling pathways that induce MMP-13 expression. The
result is a time-dependent increase in the degradation of the carti-
lage extracellular matrix.
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DDR1 and DDR2 were originally cloned as cell surface
receptor tyrosine kinases (RTKs)45e48. The mRNA tran-
scripts of the receptors are detected in several human
and mouse tissues, but mainly in bone, cartilage, skin, skel-
etal muscle, brain and heart. We examined the expression
of DDR1 and DDR2 in mouse articular cartilage. We found
that DDR2 is expressed at a very low level in the superﬁcial
layer of normal articular cartilage, whereas the expression
of DDR1 is hardly detectable. In 1997, two research groups
reported that native collagens were the DDR ligands49,50
and that a synthetic short triple-helical collagen-like (10 re-
peats of Gly-Pro-Hyp) peptide is unable to activate DDRs. A
recent study demonstrates that a region of 234 amino acid
residues within type II collagen molecules contains a spe-
ciﬁc binding site for DDR2, that type II collagen is recog-
nized preferentially by DDR2 and that the N-terminal
discoidin homology (DS) domain of DDR2 is required for
the interaction of DDR2 with type II collagen51. Ddr2-
deﬁcient mice were generated by gene-targeting tech-
niques and mutant mice exhibit short stature probably due
to decreased proliferation of chondrocytes in growth
plates52. One intriguing ﬁnding is that the overexpression
of DDR2 in ﬁbroblast-like cell lines enhances the expres-
sion of MMP-1. This prompted us to investigate if DDR2
controls the synthesis of matrix-degrading enzymes in
chondrocytes.
The results from our in vivo studies demonstrate that the
expression of DDR2 and MMP-13 and the level of MMP-
derived CII-f are increased in articular cartilage of knee
and TM joints in Col9a1/ and cho/þ mice25,26,53. We
also have found that the expression of DDR2 and MMP-
13 and the level of MMP-derived CII-f are elevated in the ar-
ticular cartilage of mice in which OA is induced surgically
and in articular cartilage of human OA hip joints obtained
from joint replacement surgeries54. This indicates that the
increased expression of these genes is not unique to cases
of genetic OA caused by mutations in cartilage collagens,
but is also seen in cases where the initiating event is joint
instability or some other non-genetic event. To understand
whether or not the increased expression of DDR2 and
MMP-13 in articular cartilage are independent events, we
performed a series of in vitro experiments55. Results from
these experiments demonstrate that (1) the level of MMP-
13 mRNA is elevated in human chondrocytes and mouse
primary chondrocytes cultured on native type II collagen
for 24 h. Surprisingly, we found that the level of DDR2
mRNA is also increased in human and mouse chondrocytes
cultured on native type II collagen. This indicates that chon-
drocytes exposed to native type II collagen for 24 h are in-
duced to express increased levels of DDR2 and MMP-13
mRNA. In contrast, the mRNAs levels of MMP-1, MMP-3,
MMP-8, ADAMTS-4, ADAMTS-5 and IL-1 were not in-
creased in the cells. (2) When human chondrocytes were
cultured on denatured type II collagen (gelatin), the levels
of expression of MMP-13 and DDR2 mRNA were not ele-
vated, suggesting that chondrocytes respond in a speciﬁc
manner to triple-helical type II collagen. (3) The overexpres-
sion of full-length DDR2 cDNA results in increased level of
MMP-13 mRNA and overexpression of a truncated DDR2
cDNA (lacking the protein tyrosine kinase of the cytoplas-
mic domain of the receptor) decreases the expression of
MMP-13 mRNA in cells cultured on type II collagen for
24 h. In addition, DDR2 lacking the type II collagen binding
domain (discoidin domain) of the receptor has no effect onthe expression of MMP-13 mRNA and receptor itself, indi-
cating that the interaction of chondrocytes with type II colla-
gen is required for the increased MMP-13 mRNA levels in
chondrocytes. (4) Ras/Raf/MEK/ERK and p38 signaling
pathways are involved in the increased expression of
MMP-13 in chondrocytes by type II collageneDDR2 interac-
tion. (5) IL-1b is not an intermediate in the DDR2 signaling
pathway involved in the up-regulation of MMP-13 in chon-
drocytes. (6) DDR2 and integrin a5b1 signaling pathways
have a synergistic effect on the expression of MMP-13 in
chondrocytes, suggesting that DDR2 signaling is indepen-
dent of a5b1 signaling. (7) DDR2 signaling increases the
transcriptional activity of the MMP-13 promoter in chondro-
cytes. Based on these data, we conclude that the activation
of DDR2 by type II collagen increases the expression of
MMP-13 via ERK and p38 signaling pathways in
chondrocytes.
A pathogenetic mechanism for OA
in Col9a1L/L and cho/D mice
We hypothesize that once the collageneproteoglycan
network in the extracellular matrix of cartilage is disrupted/
weakened, chondrocytes become more vulnerable to
mechanical stress. Under these conditions, even normal
mechanical loads can activate chondrocytes. Thus, we ob-
serve increased chondrocyte activities at early stages of OA
in mice, including chondrocyte clustering (proliferation) and
increased synthesis of proteoglycans. Over time, the acti-
vated chondrocytes synthesize and release matrix-degrad-
ing enzymes, which degrade proteoglycans. One of the
consequences of proteoglycan degradation is enhanced ex-
posure of chondrocytes to type II collagen ﬁbrils. Type II col-
lagen ﬁbrils are present within territorial and interterritorial
locations in normal articular cartilage, with little or no type
II collagen close to the chondrocyte surface56. Interaction
of chondrocytes with type II collagen ﬁbrils may result in
enhanced signaling through DDR2. The activation of
DDR2 induces the expression of MMP-13 as well as the ex-
pression of DDR2 itself. MMP-13 degradation of type II col-
lagen results in CII-f, which in turn may bind to integrins
such as a2b1 to activate signals that further increase the
synthesis of MMP-13 (Fig. 1). The result is a feedback am-
pliﬁcation loop that enhances the degradation of articular
cartilage. The end result is the irreversible destruction of ar-
ticular cartilage. Thus, type II collagen in close contact with
the cell surface can regulate its own proteolysis via its cell
membrane receptor.
Although our data demonstrate that type II collagen-
induced DDR2 increases the expression of MMP-13 in
chondrocytes by activating ERK and p38 pathways, we
do not believe that ERK and p38 are appropriate therapeu-
tic targets for slowing OA progression, since the signaling
pathways in which they participate have signiﬁcant biologi-
cal roles in many different cell types. A better target may be
a common chondrocyte-speciﬁc down-stream effector of
ERK and p38, such as one of the mitogen kinases (MKs).
In addition, the development of a chondrocyte-speciﬁc
antagonist of DDR2 may also be of interest in the effort to
develop novel therapies for OA.
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